Literature DB >> 1417048

How much nebulised budesonide reaches infants and toddlers?

K C Lødrup Carlsen1, K Nikander, K H Carlsen.   

Abstract

The amount of budesonide suspension actually delivered to six subjects (aged 4-30 months) by a jet nebuliser and spacer system (System 22) was determined. Two nebulisations were performed in each subject using a filter at the exhalation outlet of the inhalation chamber. An inhalation filter was additionally attached between the facemask and the spacer in the first test. The drug was inhaled during the second test. The nebuliser equipment was washed with ethanol and the amount of drug deposited was determined. The amount of budesonide deposited in the exhalation filter increased when the inhalation filter was omitted. Only 14% of the nominal dose (500 micrograms) of budesonide was found in the inhalation filter, increasing from nine to 19% with increasing age. Approximately 75% of the nominal dose was found in the nebuliser equipment. These findings must be considered when deciding the nominal dose of budesonide suspension to be given to infants and toddlers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417048      PMCID: PMC1793612          DOI: 10.1136/adc.67.9.1077

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  4 in total

Review 1.  Aerosol therapy in the newborn.

Authors:  M Silverman
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

2.  Why nebulise for more than five minutes?

Authors:  C O'Callaghan; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

3.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

Authors:  B M Zainudin; M Biddiscombe; S E Tolfree; M Short; S G Spiro
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

4.  Delivery of aerosolized medication to intubated babies.

Authors:  K L Watterberg; A R Clark; H W Kelly; S Murphy
Journal:  Pediatr Pulmonol       Date:  1991
  4 in total
  7 in total

1.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 2.  A risk-benefit assessment of corticosteroids in the management of croup.

Authors:  R W Yates; I J Doull
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

3.  Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis.

Authors:  A Cade; K G Brownlee; S P Conway; D Haigh; A Short; J Brown; D Dassu; S A Mason; A Phillips; R Eglin; M Graham; A Chetcuti; M Chatrath; N Hudson; A Thomas; P A Chetcuti
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

Review 4.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

5.  Systemic availability and pharmacokinetics of nebulised budesonide in preschool children.

Authors:  L Agertoft; A Andersen; E Weibull; S Pedersen
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

6.  Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension.

Authors:  P Ilangovan; S Pedersen; S Godfrey; K Nikander; N Noviski; J O Warner
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

7.  Influence of spacer device on drug delivery to young children with asthma.

Authors:  L Agertoft; S Pedersen
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.